Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
Condition(s):Central Nervous System LymphomaLast Updated:May 18, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Central Nervous System LymphomaLast Updated:May 18, 2023Recruiting
Condition(s):SensitivityLast Updated:January 11, 2022Not yet recruiting
Condition(s):Leptomeningeal MetastasisLast Updated:March 6, 2024Not yet recruiting
Condition(s):Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor Receptor; Leptomeningeal MetastasisLast Updated:April 10, 2023Not yet recruiting
Condition(s):Non-small Cell Lung CancerLast Updated:June 24, 2022Recruiting
Condition(s):Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell LungLast Updated:January 25, 2024Recruiting
Condition(s):Lung Cancer Stage IILast Updated:July 21, 2021Not yet recruiting
Condition(s):Metastatic Salivary Gland Carcinoma; Recurrent Salivary Gland Carcinoma; Stage IV Major Salivary Gland Cancer AJCC v8Last Updated:December 7, 2023Recruiting
Condition(s):Non-squamous Non-small Cell Lung CancerLast Updated:June 20, 2019Recruiting
Condition(s):Leptomeningeal MetastasisLast Updated:September 30, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.